tenatumomab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 450329765

| image =

| type = mab

| mab_type = mab

| source = o

| target = Tenascin C

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 1412891-40-7

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 7C201CLB71

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| chemical_formula =

| molecular_weight =

}}

Tenatumomab is a monoclonal antibody designed for the treatment of cancer.{{cite journal | title = International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 60 | journal = WHO Drug Information | volume = 22 | issue = 3 | pages = 244 | date = 2008 | url = https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl60.pdf | publisher = World Health Organization }}{{cite journal | vauthors = Gritt G, Gianatt A, Petronzeii F, De Santis R, Pavoni C, Rossi RL, Cattaneo L, Spagnoli LG, Ferrar S, Ross A, Barbu AM, Rambald A | title = Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy | journal = Oncotarget | volume = 9 | issue = 24 | pages = 17256 | date = March 2018 | pmid = 29683132 | pmc = 5908322 | doi = 10.18632/oncotarget.25064 }}